Sarah Heilshorn

Sarah Heilshorn

Professor, Materials Science and Engineering
Professor (By courtesy), Chemical Engineering
Professor (By courtesy), Bioengineering
Member, Bio-X
Member, Cardiovascular Institute
Member, Wu Tsai Human Performance Alliance
Member, Maternal & Child Health Research Institute (MCHRI)
Affiliate, Precourt Institute for Energy
Faculty Fellow, Sarafan ChEM-H
Member, Wu Tsai Neurosciences Institute
PhD, Caltech, Chemical Engineering (2004)
MS, Caltech, Chemical Engineering (2000)
BS, Georgia Tech, Chemical Engineering (1998)
Affiliation:
Affiliated Faculty
Heilshorn Laboratory Site
Stanford Profile
heilshorn@stanford.edu
Heilshorn's interests include biomaterials in regenerative medicine, engineered proteins with novel assembly properties, microfluidics and photolithography of proteins, and synthesis of materials to influence stem cell differentiation. Current projects include tissue engineering for spinal cord and blood vessel regeneration, designing injectable materials for use in stem cell therapies, and the design of microfluidic devices to study the directed migration of cells (i.e., chemotaxis).

Related Projects

Wu Tsai Neurosciences Institute
Interdisciplinary Scholar Award
2015
Enabling cell-based therapy of spinal cord injury through injectable hydrogels

Spinal cord injury (SCI) causes permanent damage to about 12,000 new patients in the US each year, primarily young adults. A common result of SCI is paralysis, and unfortunately, less than 1% of SCI patients have full neurological recovery by the time of hospital discharge.

Wu Tsai Neurosciences Institute
Interdisciplinary Scholar Award
2018
Sustained release of growth factors from bioengineered synthetic "cells" for treating spinal cord injury

Spinal cord injury (SCI) is a debilitating condition that affects young adults between the ages of 16 and 30, which leads to lifelong medical and financial burdens. SCI still results in a decreased quality-of-life and lower life expectancy for patients. This is due in part to the lack of a regenerative-based therapeutic approach to treating SCI in the clinic.

Related News

More News